Latest News and Press Releases

LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy Positive data supports the potential of the iN-LIfT platform to...

LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...

LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs LIfT announces successful production of first-in-class neutrophil based cell therapy from...

-         IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model  -         IMAN is the world’s first neutrophil-based cell therapy, generated...

-         IMAN demonstrated potent direct killing of a patient derived pancreatic ductal adenocarcinoma tumouroid model   -         IMAN is the world’s first neutrophil-based cell therapy, generated...

LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...

LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...

LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19...

LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19...

LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models London, 14th September 2022 – LIfT BioSciences today...